|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The gene expression pattern of GRK2 and β2-adrenoceptor as molecular markers of cardiac dysfunction was altered in patients with severe PR compared with controls and was similar to expression in patients with advanced HF.
|
30104167 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Heart failure leads to altered β2-adrenoceptor/cyclic adenosine monophosphate dynamics in the sarcolemmal phospholemman/Na,K ATPase microdomain.
|
30165515 |
2019 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We propose that the molecular switch for the loss of transverse tubules in HF and their restoration following tadalafil treatment involves the BAR domain protein Amphiphysin II (BIN1) and the restoration of catecholamine sensitivity is through reductions in G-protein receptor kinase 2, protein phosphatase 1 and protein phosphatase 2 A abundance following phosphodiesterase 5 inhibition.
|
31043634 |
2019 |
|
Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to β-blockers in patients with heart failure.
|
30374408 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
β2-adrenergic receptor autoantibodies alleviated myocardial damage induced by β1-adrenergic receptor autoantibodies in heart failure.
|
29746700 |
2018 |
|
Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The present study shows that the Gln27Gln genotype of β2-AR is the most predominant while the Glu27Glu is the least prevalent in our HF population.
|
28933308 |
2018 |
|
Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
After controlling for demographics, functional status, and treatment adherence, polymorphisms in ADRB1, ADRB2 and eNOS are associated with healthcare outcomes in heart failure patients.
|
22543981 |
2012 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our data show that enhanced β(2)AR phosphorylation by GRK, in addition to PKA, leads the receptor to G(i)-biased signaling, which, in turn, contributes to the pathogenesis of heart failure, marking G(i)-biased β(2)AR signaling as a primary event linking upregulation of GRK to cardiac maladaptive remodeling, failure and cardiodepression.
|
22179058 |
2012 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
RGD |
Thus, the redistribution of beta(2)ARs in heart failure changes compartmentation of cAMP and might contribute to the failing myocardial phenotype.
|
20185685 |
2010 |
|
Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
A total of 226 patients with end-stage HF (ejection fraction ≤35%) were genotyped for the two β(1)AR SNPs and the three β(2)AR SNPs.
|
20803192 |
2010 |
|
Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Beta-2 adrenergic receptor gene polymorphisms Gln27Glu, Arg16Gly in patients with heart failure.
|
19886995 |
2009 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
RGD |
Therapeutic efficacy of a combination of a beta1-adrenoreceptor (AR) blocker and beta2-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a beta1-AR blocker plus angiotensin-converting enzyme inhibitor.
|
19587314 |
2009 |
|
Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Finally, the Arg16Gln27 beta(2)-AR haplotype appears to be - at least in human vascular and bronchial smooth muscles - rather susceptible to agonist-induced desensitization (in contrast to the recombinant cell system findings), and might have some predictive value for poor outcome of heart failure.
|
18353108 |
2008 |
|
Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Numerous studies have demonstrated that beta(1)- and beta(2)-adrenergic receptor gene (ADRB1 and ADRB2) variants influence cardiovascular risk and beta-blocker responses in hypertension and heart failure.
|
18615004 |
2008 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
There are many findings about the changes of beta(1)- and beta(2)-AR in heart failure (HF).
|
19120134 |
2008 |
|
Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Moreover, the Arg16Gln27 beta-2 AR haplotype might have some predictive value for poor outcome of heart failure.
|
17916379 |
2008 |
|
Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Allelic variants at codons 16 and 27 of the beta(2)-adrenergic receptor gene (ADRB2) have shown clinical and pharmacological implications in asthma, hypertension, ischemic heart failure, diabetes, obesity, and cystic fibrosis.
|
18440968 |
2008 |
|
Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure.
|
17223428 |
2007 |
|
Heart failure
|
0.300 |
GeneticVariation
|
disease |
LHGDN |
Arg16/Gly beta2-adrenergic receptor polymorphism alters the cardiac output response to isometric exercise.
|
15994241 |
2005 |
|
Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We conclude that the beta(2)AR polymorphisms Ile164, Gly16, and the combination of Gly16 and Gln27 are associated with depressed exercise performance in HF and represent a genetically determined factor in the pathophysiology of HF.
|
10785504 |
2000 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
To investigate whether alterations in betaAR function contribute to the development of myocardial failure, transgenic mice with cardiac-restricted overexpression of either a peptide inhibitor of betaARK1 or the beta2AR were mated into a genetic model of murine heart failure (MLP-/-).
|
9618528 |
1998 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In contrast, beta 2-adrenergic receptor mRNA levels were apparently unaffected by heart failure.
|
8522688 |
1996 |